Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
-
- C. Paul
- Department of Dermatology Toulouse University Hôpital Larrey, 24 Chemin de Pouvourville Toulouse 31000 France
-
- J. Cather
- Modern Research Associates Dallas TX U.S.A.
-
- M. Gooderham
- Skin Centre for Dermatology Peterborough ON Canada
-
- Y. Poulin
- Centre de Recherche Dermatologique du Québec Métropolitain Québec QC Canada
-
- U. Mrowietz
- Psoriasis Center at the Department of Dermatology University Medical Center Schleswig‐Holstein Campus Kiel Germany
-
- C. Ferrandiz
- University Hospital Germans Trias i Pujol Badalona Spain
-
- J. Crowley
- Bakersfield Dermatology Bakersfield CA U.S.A.
-
- C. Hu
- Celgene Corporation Warren NJ U.S.A.
-
- R.M. Stevens
- Celgene Corporation Warren NJ U.S.A.
-
- K. Shah
- Celgene Corporation Warren NJ U.S.A.
-
- R.M. Day
- Celgene Corporation Warren NJ U.S.A.
-
- G. Girolomoni
- University of Verona Verona Italy
-
- A.B. Gottlieb
- Tufts Medical Center Boston MA U.S.A.
収録刊行物
-
- British Journal of Dermatology
-
British Journal of Dermatology 173 (6), 1387-1399, 2015-11-07
Oxford University Press (OUP)
